ALK and ROS1 non-small-cell lung cancer: two molecular subgroups sensitive to targeted therapy
Journal: Lancet Respir Med
Veröffentlichung: 2. Dezember 2014
Phase II Study of Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer: Metastatic Non-small Cell Lung Cancer
Journal: Int J Radiat Oncol Biol Phys
Veröffentlicht: 1. Dezember 2014
Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer
Journal: Nat Med. 2014 Sep;20(9):1027-34. doi: 10.1038/nm.3667.Epub 2014Aug 31
Veröffentlichung: 20. September 2014 (Epub 31. August 2014)
Modeling Tumor Dynamics and Overall Survival in Advanced Non-Small-Cell Lung Cancer Treated with Erlotinib
Journal: J Thorac Oncol
Veröffentlichung: 12. September 2014 (Epub ahead of print)
CD74-NRG1 Fusions in Lung Adenocarcinoma
Journal: Cancer Discov. 2014 Apr;4(4):415-22. doi: 10.1158/2159-8290.CD-13-0633. PMID: 24469108
Veröffentlichung: 4. April 2014 (Epub 27. Januar 2014)